This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|January 28, 2010
Senate Introduces Nanotechnology Safety Legislation
Author(s)Stephanie Sutton
Two US senators have introduced the Nanotechnology Safety Act of 2010, which would establish a program within the US Food and Drug Administration to assess the health and safety implications of nanotechnology in everyday products.
Advertisement
Two US senators have introduced the Nanotechnology Safety Act of 2010, which would establish a program within the US Food and Drug Administration to assess the health and safety implications of nanotechnology in everyday products. The legislation would also develop best practices for companies employing nanotechnology.
“Nanotechnology is one of the most important and enabling technologies being developed right now and it has hundreds of promising applications-from new cancer treatments to improved military machinery to stain-resistant clothes. As these products are developed and used, we must understand any potential risks to human health, safety, or the environment,” Sen. Mark Pryor (D-AR), who introduced the legislation with Sen. Benjamin L. Cardin (D-MD), said in a
According to Pryor, FDA already has facilities in place that could conduct the scientific studies required under the legislation-namely the National Center for Toxicological Research (NCTR) in Jefferson, Arizona, and its consolidated headquarters in White Oak, Maryland. Both locations provide the agency with scientific technology, training, methods development, and technical expertise.
“The NCTR has built a record of excellence in its mission to provide scientifically sound basis for FDA decisions. This success is due in part to its strong partnerships with researchers in government, the private sector, and academia,” said Pryor in the statement.
Cardin added: “The high-tech infrastructure at the new consolidated headquarters at White Oak provides the FDA with an opportunity for innovation and more effective use of technology to meet challenges in product safety, global markets, and increased consumer demand.”
According to the statement, there are more than 600 known commercial uses of nanotechnology. In 2004, the US National Science Foundation estimated that new nanotechnology-based products would contribute 2 million jobs and $1 trillion in revenue to the global economy by 2015.
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement